Company intelligence / Profile preview
BioRay Pharmaceutical
Shanghai, Shanghai, Chinabioraypharm.com ↗
- Ownership
- Private
- Employees
- ~1400
- Development stage
- Commercial
01
Overview
BioRay has six marketed products in China across oncology and autoimmune indications. Its lead novel asset Anruixi® demonstrated non-inferiority to Rituximab in a head-to-head Phase III trial for DLBCL with higher complete response rates. The company is advancing next-generation ADCs such as BR111 targeting ROR1 into clinical trials. Over ten additional candidates are in clinical or IND-enabling stages.
- Therapeutic areas
- OncologyDermatologyImmunologyGastroenterology
- Modalities
- Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)BiosimilarsFusion proteins
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
PAG Private EquityZhejiang Hisun Pharmaceutical Co., Ltd.Sun Yat-sen Memorial Hospital
Beyond the preview
Go deeper on BioRay Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioRay Pharmaceutical.